However, several side effects and toxicities, such as hematological toxicities and diabetes-like symptoms (e.g., hyperglycemia and hyperinsulinemia) in the case of IGF1R-targeted therapies and hematological toxicities (e.g., leukopenia, neutropenia, and thrombocytopenia) in the case of Src inhibitors, have been reported in recent clinical trials utilizing these drugs [43–45]. The gene discussed is IGF1R; the disease is Thrombocytopenia.